Purpose

The aim of this study is to assess whether delaying early flow through the Ahmed tube shunt may improve the post-operative surgical outcomes and provide a more predictable outcome. To assess this the investigator will conduct a, randomized prospective, multi-centered study with collaborators at WashU in St. Louis, Duke University, Indiana University and the University of Pittsburgh. Participants will be randomized to have an AGV placement with tube ligation (no-early flow) and without ligation (allowing for early flow). IOP will be measured at day one, week one, and months, one, three six, and twelve. Additionally, clinical data regarding number of glaucoma medications, and complications post-operative complications will also be collected.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Subjects with age at screening ≥ 18 years - Inadequately controlled glaucoma or ocular hypertension - Ahmed valve implant as the planned surgical procedure - Patients with primary glaucomas (Primary Open Angle Glaucoma or Primary Angle Closure Glaucoma) or pseudoexfoliation, pigmentary and traumatic glaucoma with or without a previous failed trabeculectomy or other intraocular surgery. - Primary tubes included - Investigators to recruit consecutively all eligible patients from their clinics. - Capable and willing to provide consent

Exclusion Criteria

  • Subjects with NLP vision - Subjects unable/unwilling to provide informed consent - Unavailable for regular follow up - Previous cyclodestructive procedure - Prior scleral buckling procedure or other external impediment to drainage device implantation - Presence of silicone oil - Vitreous in the anterior chamber sufficient to require a vitrectomy - Uveitic glaucoma - Neovascular glaucoma - Nanophthalmos - Patients with pathology that may cause elevated episcleral venous pressure - Procedure combined with ocular surgery other than cataract surgery (i.e. combined tube-cataract surgery is okay) - Any abnormality other than glaucoma in the study eye that could affect tonometry.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Standard Implantation Standard Implantation
  • Procedure: Standard Implantation
    Traditional Ahmed plantation without vicryl ligature
Tied off Tube Tied off Tube
  • Procedure: Tied off Tube
    Ahmed implantation with vicryl ligature

Recruiting Locations

Washington University in St. Louis and nearby locations

Washington University
St Louis 4407066, Missouri 4398678 63108
Contact:
Amer Al Badwai
314-286-2946
aamer@wustl.edu

More Details

NCT ID
NCT05685485
Status
Recruiting
Sponsor
Washington University School of Medicine

Study Contact

Amer Al Badwai
314-286-2946
aamer@wustl.edu

Detailed Description

The purpose of this study is to compare the post-operative surgical outcomes and complication rates in patients with different surgical techniques in the Ahmed FP7 glaucoma valve implant (New World Medical, Inc., Rancho Cucamonga, CA). In particular, the investigator wishes to assess whether delaying early aqueous flow by using a vicryl ligature (as done in most non-valved glaucoma drainage device implantation) will reduce the hypertensive phase, reduce early encapsulation, and optimize healing dynamics to allow for improved long term IOP results compared to standard implantation techniques. Aggressive early aqueous flow may introduce inflammatory mediators that may increase fibrosis during wound healing. Furthermore, mechanical compression of the tissue surrounding the plate may further lead to a denser capsule and limit aqueous diffusion through Tenon's and conjunctiva. For these reasons, the investigator postulate's that the limitation of early aqueous flow through the Ahmed valve will reduce the rates of hypertensive phase, lead to a thinner and less encapsulated bleb, reduce complication rates such as hypotony, and lead to overall improvement in long-term IOP reduction.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.